Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, on the utility of the androgen receptor inhibitor ODM-201 for the treatment of castration-resistant prostate cancer (CRPC).
- In phase I and II multinational trials, favorable results have been observed regarding PSA kinetics modulation
- The organic structure of ODM-201 seems to cause the agent to have a much lower penetration through the blood-brain barrier
- The efficacy of ODM-201 is being measured in terms of its impact on radiographic disease, PSA, and the androgen receptor
- ODM-201 has been studied in patients prior to and following chemotherapy, as well as in patients who have and have not received abiraterone
- Additional trials are being planned to analyze safety, efficacy, and tolerability
- ODM-201 will be studied in a large trial of non-metastatic patients